Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

869
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
869
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Skin Cancer01:30

Skin Cancer

5.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Factors in Primary Head and Neck Cutaneous Squamous Cell Carcinoma: A Large-Scale, Multi-Institutional Competing-Risks Analysis.

Journal of surgical oncology·2026
Same author

Collaboration Between Mohs and Surgical Subspecialists in the Treatment of Advanced Nonmelanoma Skin Cancer.

Head & neck·2026
Same author

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026
Same author

Liquid Biopsy in Cutaneous Oncology: Current Practice and Future Directions.

Journal of the American Academy of Dermatology·2026
Same author

Improving Prognostication for Cutaneous Squamous Cell Carcinoma.

The British journal of dermatology·2026
Same author

Mohs micrographic surgery versus wide local excision for recurrent cutaneous squamous cell carcinoma.

JAAD international·2026

Related Experiment Video

Updated: Dec 21, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.0K

Field cancerization: Treatment.

Christine M Cornejo1, Anokhi Jambusaria-Pahlajani2, Tyler J Willenbrink2

  • 1Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Journal of the American Academy of Dermatology
|May 11, 2020
PubMed
Summary

Field cancerization treatment aims to prevent keratinocyte carcinoma. Treatment choice balances cancer extent, lesion number, efficacy, cost, side effects, and patient preference for optimal outcomes.

Keywords:
actinic keratosescutaneous squamous cell carcinomafield cancerizationkeratinocyte carcinomasolid organ transplant recipient

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.5K

Related Experiment Videos

Last Updated: Dec 21, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.5K

Area of Science:

  • Dermatology
  • Oncology
  • Cutaneous Medicine

Background:

  • Field cancerization increases the risk of developing keratinocyte carcinoma.
  • Effective management requires understanding the extent of subclinical atypia and visible lesions.

Purpose of the Study:

  • To provide a framework for evidence-based decision-making in field cancerization treatment.
  • To guide selection of appropriate therapies based on clinical and patient factors.

Main Methods:

  • Review of current therapeutic approaches for field cancerization.
  • Analysis of factors influencing treatment selection, including efficacy, cost, and patient preference.

Main Results:

  • Field therapies are effective for clinically visible disease and subclinical atypia.
  • Lesion-directed therapies are indicated for difficult-to-treat lesions or when histologic diagnosis is necessary.
  • Combination therapy is beneficial for extensive field cancerization.

Conclusions:

  • Treatment selection for field cancerization is multifactorial.
  • A combined approach of field-directed and lesion-directed therapies offers comprehensive management.
  • Evidence-based decision-making is crucial for optimizing patient outcomes.